Table 3.
Univariate differences between V1 and V2
| RR (n = 57) | TR (n = 30) | Welsh two-sample t test | ||||||
|---|---|---|---|---|---|---|---|---|
| Difference variable | m1 | sd1 | m0 | sd0 | T | df | PV | Cohen_d |
| PANSS.Tot | 3.7 | 12.1 | −7.2 | 9.8 | 4.4 | 65.1 | <0.001 | 0.961 |
| PANSS.Pos | 0.8 | 3.8 | −1.6 | 4.3 | 2.5 | 48.4 | 0.009 | 0.594 |
| PANSS.Neg | 1.2 | 4.4 | −2.4 | 4.1 | 3.7 | 58.9 | <0.001 | 0.827 |
| PANSS.GP | 1.8 | 5.5 | −3.5 | 5 | 4.4 | 60 | <0.001 | 0.991 |
| PSP | 4.4 | 9.3 | −8.3 | 11.5 | 5.1 | 48.1 | <0.001 | 1.255 |
| ERFCS.Tot | 2.2 | 18.5 | −4.1 | 15.9 | 1.6 | 60.6 | 0.061 | 0.357 |
| Simil.NB | 0.6 | 2.8 | −1 | 2.6 | 2.5 | 64.5 | 0.008 | 0.554 |
| BEMRI.NB | −0.1 | 1.5 | 0.2 | 1.9 | −0.9 | 49.8 | 0.823 | −0.229 |
| BEMRD.NB | −0.1 | 1.7 | 0.1 | 2 | −0.4 | 54.8 | 0.647 | −0.090 |
| TMTA.Time | 0.9 | 8 | −1.5 | 16.4 | 0.8 | 37.3 | 0.226 | 0.206 |
| TMTB.Time | −2.6 | 38.3 | 4.7 | 33 | −0.9 | 63.1 | 0.808 | −0.197 |
| Coding.NB | −0.3 | 7.6 | 0.6 | 6 | −0.6 | 72.2 | 0.73 | −0.134 |
| PerSo.Tot | 0.5 | 4.2 | −0.8 | 4.7 | 1.3 | 55.5 | 0.1 | 0.309 |
| Shopping.time | −0.1 | 2.7 | 0.3 | 2.4 | −0.7 | 68 | 0.755 | −0.154 |
| MASC.MC | −0.1 | 4.1 | 0.1 | 4.6 | −0.2 | 53.3 | 0.587 | −0.053 |
| MASC.Hy | 0.2 | 2.3 | −0.3 | 3.2 | 0.8 | 44.3 | 0.214 | 0.205 |
| MASC.Ho | −0.4 | 3.4 | 0.8 | 3.5 | −1.5 | 56.2 | 0.934 | −0.360 |
| MASC.Abs | 0.2 | 2.1 | −0.3 | 2.8 | 0.8 | 46.3 | 0.216 | 0.199 |
| f.NART | 0.2 | 4.4 | −0.3 | 4.9 | 0.5 | 55.3 | 0.315 | 0.115 |
| ACSo.Tot | 0.1 | 7.4 | −0.2 | 6.6 | 0.2 | 66.9 | 0.435 | 0.037 |
| SERS.posit | 0.5 | 9.1 | −0.7 | 9.2 | 0.6 | 61.6 | 0.286 | 0.133 |
| SERS.negat | −0.2 | 6.1 | 0.4 | 7.6 | −0.4 | 52.6 | 0.639 | −0.088 |
| QCAE.tot | −1.6 | 6.9 | 2.5 | 7.3 | −2.5 | 59.1 | 0.992 | −0.583 |
| ISMI.Tot | 0 | 0.3 | 0 | 0.3 | 1.1 | 64 | 0.141 | 0.250 |
| ISMI.Alien | −0.1 | 0.5 | 0.1 | 0.5 | −1.7 | 62.3 | 0.952 | −0.395 |
| ISMI.Stereo | 0.1 | 0.4 | −0.1 | 0.4 | 2.1 | 61.8 | 0.019 | 0.495 |
| ISMI.Discri | 0.1 | 0.5 | −0.1 | 0.4 | 1.7 | 66.5 | 0.047 | 0.389 |
| ISMI.Socwith | 0 | 0.5 | 0 | 0.4 | 0.4 | 73.8 | 0.343 | 0.088 |
| ISMI.Rstig | −0.1 | 0.3 | 0.1 | 0.5 | −1.4 | 46.4 | 0.918 | −0.358 |
| AIHQ.Host | 0 | 0.6 | −0.1 | 0.8 | 0.8 | 46.2 | 0.224 | 0.195 |
| AIHQ.Intent | 0.1 | 0.9 | −0.2 | 1.1 | 1.4 | 51.7 | 0.087 | 0.339 |
| AIHQ.Anger | 0 | 0.7 | −0.1 | 1.2 | 0.3 | 41.3 | 0.364 | 0.092 |
| AIHQ.Blame | 0.1 | 1 | −0.1 | 1.2 | 0.7 | 49.4 | 0.235 | 0.182 |
| AIHQ.Agres | 0.1 | 0.4 | −0.2 | 0.5 | 2.5 | 47.4 | 0.008 | 0.627 |
| AIHQ.AttRe | 0.1 | 0.8 | −0.1 | 1 | 0.9 | 46.2 | 0.176 | 0.239 |
| STORI.Mora | −0.6 | 6.5 | 1 | 6.7 | −1 | 58 | 0.841 | 0.240 |
| STORI.Awar | 0.4 | 5.4 | −0.6 | 8 | 0.5 | 43.8 | 0.294 | 0.141 |
| STORI.Prep | −0.5 | 7.5 | 0.8 | 8.1 | −0.7 | 55.7 | 0.754 | 0.166 |
| STORI.Rebuild | −0.5 | 6.5 | 0.8 | 6 | −0.9 | 63 | 0.814 | 0.208 |
| STORI.Growth | −0.5 | 8.8 | 0.7 | 5.8 | −0.7 | 73.7 | 0.758 | −0.151 |
| BUES.Tot | 0 | 0.3 | −0.1 | 0.2 | 1.4 | 69.2 | 0.088 | 0.306 |
| CPZ.EQ | 0.1 | 0.8 | −0.1 | 0.3 | 1.8 | 79.6 | 0.039 | 0.317 |
For each of the 42 outcome variables, improvement was defined as the difference between the value at V2 and V1, oriented so that a positive difference should correspond to an improvement of the patient’s condition. Each difference was adjusted by a linear regression over its confounding value at V1. The table displays the sample size mean and standard-deviation of the adjusted difference over the Expe patients, then over the TR patients, then the results (test statistic, degrees of freedom, p value) of the Walsh two-sample one-sided T test between both. A p value smaller than 0.05 indicates that the mean improvement over Expe patients is significantly higher. CPZ100eq: dose equivalent to 100 mg/day of chlorpromazine calculated according to the minimum effective dose method [49].
Abbreviations: AcSo, self-assessment of social cognition; AIHQ, Ambiguous Intentions and Hostility Questionnaire (agress, aggression bias; anger, anger score; blame, blame score; host, hostility bias; resp, attribution of responsibility); BEM-RD, BEM delayed recall; BEM-RI, BEM immediate recall; BUES, Boston University Empowerment Scale; Coding, WAIS-IV Coding subscale; Education, education level (years); ERF-CS, Social Cognition—Functional Outcomes Scale; ISMI, Internalized Stigma of Mental Illness scale (Alien, alienation subscale; discri, discrimination experience; Rstig, stigma resistance; stereo, stereotype endorsement; soc-with, social withdrawal; tot, total score); MASC, Movie for the Assessment of Social Cognition (Abs, absence of ToM; CM, correct mentalization score; Ho, hypomentalization; Hy, hypermentalization score); PANSS, Positive and Negative Syndrome Scale (positive, negative, and general psychopathology subscales); PerSo, social perception test; PSP, Personal and Social Performance Scale total score; QCAE, Questionnaire of Cognitive and Affective Empathy; SERS-SF, Self-Esteem Rating Scale-Short Form (positive and negative subscales); Simil NB, WAIS IV Similarities subtest; STORI, tage of recovery instrument (awar, awareness; growth, growth stage; mora, moratorium stage; prep, preparation stage; rebuil, rebuilding stage); TMT, Trail Making Test A and B; Bold values indicate the p-values significant at p<0.05.